Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/5/2008

CALGARY, June 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combina
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... Dallas, Texas (PRWEB) August 21, 2014 ... Global Seaweed Fertilizer Industry” is a professional ... Fertilizer market. The report provides basic Seaweed ... application, and industry chain structure as well ... international market analysis, including domestic market as ...
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation ... its plan to release financial results for the first ... 2014, after market close in the US.  ... 8:00 a.m. ET on Friday, August 29, 2014 to ... of the Company,s recent developments, followed by a question ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2
... Robotic cars attracted attention last decade with a 100-mile driverless ... put up by the U.S. government. The past ... microrobots, miniaturized mobile machines designed to perform specific tasks. And ... some think the time has come for a microrobotics challenge. ...
... CASTRES, France , July 2, 2010 Olivier ... Pierre Fabre,Group starting September 1, 2010 . , ... Until now, Olivier Bohuon , 51, ... such, he ran the,group,s entire pharmaceutical activities from Chicago ( $22 ...
... ... progenitors into specific T cell lineages to the activity of a single gene encoding a ... for the development of blood cells lineages. , ... (PRWeb UK) July 1, 2010 -- A research team in Japan has ...
Cached Biology Technology:Thermal-powered, insect-like robot crawls into microrobot contenders' ring 2Thermal-powered, insect-like robot crawls into microrobot contenders' ring 3Olivier Bohuon Joins Pierre Fabre 2The Last Checkpoint to T Cell Fate 2
(Date:8/22/2014)... strong antioxidants and can reduce free radical ... against oxidative stress? Jianbo Zhao and co-workers ... Medical University, China discovered that green tea ... neuronal apoptosis, indicating green tea polyphenols play ... under oxidative stress. The relevant study has ...
(Date:8/21/2014)... Athens, Ga. An international team of scientists including researchers ... Brassica napus commonly known as canolain the journal ... of the plant, which is used widely in farming and ... and its native Europe, but the winter crop is increasingly ... for its naturally low levels of saturated fat and rich ...
(Date:8/21/2014)... unknown process for harvesting energy and producing oxygen from ... University scientist has discovered. The discovery lays the foundation ... energy from the Sun, and understanding dense blooms like ... worldwide. A paper describing the discovery will be published ... journal Science on 21 August 2014. , ...
Breaking Biology News(10 mins):Canola genome sequence reveals evolutionary 'love triangle' 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3
... has awarded 23 grants for structural biology research totaling ... will focus on determining the shapes and functions of ... awards are part of the Protein Structure Initiative (PSI), ... goal of developing highly efficient, or high-throughput, methods for ...
... operated by Georgia Tech and Emory University has received ... support a project aimed at reducing the incidence of ... Platt, an assistant professor in the Wallace H. Coulter ... of Health (NIH) funding to develop models for identifying ...
... A new research report in the October 2010 print ... http://www.jleukbio.org ) sheds important light on how our immune systems ... bodies. The information from this research should ultimately help lead ... health care providers to prevent runaway immune reactions that can ...
Cached Biology News:NIH grants will advance studies of the form and function of proteins 2NIH grants will advance studies of the form and function of proteins 3$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 2$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 3$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 4Scientists reveal important clues to how bacteria and viruses are identified as enemies 2
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: